sabizabulin (Veru-111)

From Aaushi
Jump to navigation Jump to search

Indications

  • investigational agent for treatment of severe Covid-19

Dosage

Clinical significance

* both treatment groups were allowed to receive standard of care including remdesivir, dexamethasone, anti-IL-6 receptor antibodies, & JAK inhibitors

Mechanism of action

More general terms

References

  1. Ingram I Whopping Mortality Benefit in Severe COVID Trial. Oral sabizabulin showed 55% reduction in risk for death in hospitalized patients. MedPage Today July 7, 2022 https://www.medpagetoday.com/infectiousdisease/covid19/99610
    Barnette KG, Gordon MS, Rodriguez D Oral Sabizabulin for High-Risk, Hospitalized Adults with Covid-19: Interim Analysis. NEJM Evidence. 2022. July 6. Not indexed in PubMed https://evidence.nejm.org/doi/full/10.1056/EVIDoa2200145
    Veru Veru's Novel COVID-19 Drug Candidate Reduces Deaths by 55% in Hospitalized Patients in Interim Analysis of Phase 3 Study; Independent Data Monitoring Committee Halts Study Early for Overwhelming Efficacy. https://verupharma.com/news/verus-novel-covid-19-drug-candidate-reduces-deaths-by-55-in-hospitalized-patients-in-interim-analysis-of-phase-3-study-independent-data-monitoring-committee-halts-study-early-for-overwhelmin/

Database